Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165


Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas.

Crépin R, Goenaga AL, Jullienne B, Bougherara H, Legay C, Benihoud K, Marks JD, Poul MA.

Cancer Res. 2010 Jul 1;70(13):5497-506. doi: 10.1158/0008-5472.CAN-10-0938. Epub 2010 Jun 8.


The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor.

Qing Y, Shuo W, Zhihua W, Huifen Z, Ping L, Lijiang L, Xiaorong Z, Liming C, Daiwen X, Yu H, Wei X, Min F, Zuohua F, Guanxin S.

Cancer Immunol Immunother. 2006 Sep;55(9):1111-21. Epub 2005 Dec 8.


Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin.

Shinohara H, Fan D, Ozawa S, Yano S, Van Arsdell M, Viner JL, Beers R, Pastan I, Fidler IJ.

Int J Oncol. 2000 Oct;17(4):643-51.


Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments.

Lepelletier Y, Camara-Clayette V, Jin H, Hermant A, Coulon S, Dussiot M, Arcos-Fajardo M, Baude C, Canionni D, Delarue R, Brousse N, Benaroch P, Benhamou M, Ribrag V, Monteiro RC, Moura IC, Hermine O.

Cancer Res. 2007 Feb 1;67(3):1145-54.


A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients.

Moura IC, Lepelletier Y, Arnulf B, England P, Baude C, Beaumont C, Bazarbachi A, Benhamou M, Monteiro RC, Hermine O.

Blood. 2004 Mar 1;103(5):1838-45. Epub 2003 Oct 30.


Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.

Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA.

Cancer Res. 2008 Oct 1;68(19):8049-57. doi: 10.1158/0008-5472.CAN-08-2268.


Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies.

Taetle R, Castagnola J, Mendelsohn J.

Cancer Res. 1986 Apr;46(4 Pt 1):1759-63.


Structural, functional, and tissue distribution analysis of human transferrin receptor-2 by murine monoclonal antibodies and a polyclonal antiserum.

Deaglio S, Capobianco A, Calì A, Bellora F, Alberti F, Righi L, Sapino A, Camaschella C, Malavasi F.

Blood. 2002 Nov 15;100(10):3782-9. Epub 2002 Jul 5.


Heterogeneity of the human transferrin receptor and use of anti-transferrin receptor antibodies to detect tumours in vivo.

Panaccio M, Zalcberg JR, Thompson CH, Leyden MJ, Sullivan JR, Lichtenstein M, McKenzie IF.

Immunol Cell Biol. 1987 Dec;65 ( Pt 6):461-72.


[Expression, purification and activity analysis of anti-human transferrin receptor scFv].

Zhao LX, Yan B, Xu L, Jiang SW, Zhang YY, Yang ZX, Zhou XW, Huang PT.

Sheng Wu Gong Cheng Xue Bao. 2006 May;22(3):488-91. Chinese.


Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors.

Cazzola M, Bergamaschi G, Dezza L, D'Uva R, Ponchio L, Rosti V, Ascari E.

Cancer Res. 1991 Jan 15;51(2):536-41.


Supplemental Content

Support Center